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In this issue of Cancer Cell, Kopp and colleagues report that pancreatic ductal cells are largely refractory to
the induction of pancreatic neoplasia. Whereas a rare ductal subpopulation may still prove capable of
neoplastic transformation, these findings refocus attention on acinar and other non-ductal cell types as initi-
ators of this deadly neoplasm.While malignant tumors of the pancreas
can display a variety of histologic forms,
the term ‘‘pancreatic cancer’’ is usually
synonymous with a pathological diag-
nosis of pancreatic ductal adenocarci-
noma (PDAC). As its name implies,
PDAC has long been presumed to arise
from pancreatic ductal epithelial cells.
Along with its noninvasive precursor, pan-
creatic intraepithelial neoplasia (PanIN),
these tumors typically display a distinctly
duct-like histology, and express markers
of ductal differentiation. As demonstrated
for other tumor types, however, tumor
histology is often misleading in deter-
mining tumor lineage, and work from
Kopp et al. (2012) published in this
issue of Cancer Cell reinforces the
disputed paternity of pancreatic ‘‘ductal’’
neoplasia.
Initial clues suggesting that non-ductal
cells might serve as effective cells of
origin for pancreatic ductal neoplasia
were provided by studies involving
transgenic misexpression of individual
oncogenes under the regulation of non-ductal promoter elements, in which a
subset of resulting tumors displayed
histologic resemblance to adult ductal
epithelium (Sandgren et al., 1991). How-
ever, these similarities were ultimately
proven to be only skin-deep, as additional
studies of PanIN and PDAC revealed
activation of transcriptional programs
typically observed in embyronic pancre-
atic epithelium, but not in differentiated
duct cells (Miyamoto et al., 2003; Park
et al., 2011).
With the advent of autochthonous
mouse models of pancreatic neoplasia,
more recent studies have interrogated
individual pancreatic cell types for the
ability to generate PanIN, based upon
Cre/lox-mediated activation of oncogenic
Kras. Initial seminal work in this arena
utilized either Pdx1Cre or Ptf1aCre alleles
to activate Kras in embryonic pancreatic
progenitor cells (Aguirre et al., 2003;
Hingorani et al., 2003). While these
studies demonstrated that embryonic
activation of oncogenic Kras effectively
initiated pancreatic ductal neoplasia,they provided considerably less informa-
tion regarding the capacity of individual
adult cell lineages to similarly serve as
effective cells of origin. Based on the
availability of appropriate Cre driver
lines, this adult capacity was first interro-
gated in pancreatic acinar cells. Using
either a Nestin-Cre driver to activate
oncogenic Kras in exocrine progenitor
cells and their acinar cell descendants
(Carrie`re et al., 2007) or a variety of induc-
ible Cre lines to activate Kras in adult
acinar cells (De La O et al., 2008; Guerra
et al., 2007; Habbe et al., 2008), these
studies provided strong evidence that
acinar cells could indeed serve as effec-
tive biologic parents for pancreatic ductal
neoplasia. In these studies, the ability of
adult acinar cells to generate PanIN was
dramatically accelerated in the context
of associated pancreatitis, a known risk
factor for the human disease. Additional
studies suggested that a permissive
inflammatory microenvironment could
broadly bestow PanIN-parenting capabil-
ities, as even insulin-expressing cellsecember 11, 2012 ª2012 Elsevier Inc. 701
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Figure 1. Competence of Individual Pancreatic Cell Types to Generate Pancreatic
Intraepithelial Neoplasia in Response to Oncogenic Kras Activation
(A) Kras activation in early pancreatic progenitor cells and their progeny leads to effective pancreatic intra-
epithelial neoplasia (PanIN) initiation.
(B) Kras activation in later exocrine-dedicated progenitor cells and their acinar cell progeny also results
in PanIN.
(C)Kras activation in differentiated acinar cells, but not themost common ductal epithelial lineage, leads to
effective PanIN initiation. In an inflammatory microenvironment, insulin-expressing endocrine cells can
also generate PanIN. Low-abundance pancreatic ductal/centroacinar subpopulations may still remain
to be evaluated as effective cells of origin. Red indicates cell types capable of forming PanIN; yellow indi-
cates cells resistant to PanIN; and gray indicates known and potentially unknown cell populations still
unevaluated.
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Previewswere shown to be capable of generating
PanIN in the context of associated
pancreatitis (Gidekel Friedlander et al.,
2009).
Ironically, these studies demonstrating
that pancreatic ductal neoplasia could
be generated from a variety of non-ductal
cell types were all completed prior to
a similar definitive evaluation in actual
ductal epithelial cells. However, a long-
awaited detailed glimpse at the parental
capacities of the ductal epithelial lineage
is now available. In this new study, Kopp
et al. (2012) directly compare the effi-
ciency of PanIN formation following cell
type-specific activation of oncogenic
Kras in the acinar lineage using a
Ptf1aCreER line and in the ductal/centroa-
cinar lineage using a Sox9CreER line. For
both lines, postnatal tamoxifen adminis-
tration induced recombination in a
similar proportion of target cells. Similar
to prior studies using other acinar cell-
specific Cre driver lines, the authors
observed potent induction of PanIN
lesions in Ptf1aCreER; KrasG12D mice, an
effect that was further accelerated by
concomitant pancreatitis. However there
was minimal-to-no PanIN induction in
Sox9CreER; KrasG12D mice, even in the702 Cancer Cell 22, December 11, 2012 ª20presence of pancreatitis. Even when dis-
crepant PanIN frequencies were normal-
ized based on the greater abundance of
acinar cells, the difference in PanIN-
generating capabilities between the two
lineages remained striking, with acinar
cells at least 100-fold more effective
than ductal/centroacinar cells in gener-
ating PanIN. In addition, the authors
demonstrated that, within the acinar
lineage, Sox9 itself was required for effi-
cient PanIN induction, and that Sox9
overexpression enhanced both pancrea-
titis-associated metaplasia and Kras-
induced PanIN formation within the acinar
lineage.
Together, these comprehensive studies
demonstrate that, while differentiated
acinar cells are fully capable of generating
PanIN through requisite Kras-induced
Sox9 activation, ductal and centroacinar
cells already expressing Sox9 are dramat-
ically resistant to Kras-induced neoplastic
transformation. In conjunction with prior
studies, these findings lead to the startling
recognition that the predominant Sox9-
expressing ductal epithelial lineage re-
presents the only pancreatic epithelial
lineage evaluated to date that is unable
to efficiently generate PanIN (Figure 1).12 Elsevier Inc.Before entirely disqualifying ductal and
centroacinar cells from consideration as
capable PanIN parents, it is necessary to
consider a broad number of remaining
questions and possibilities. First, it must
be recognized that, while Sox9 appears
to be expressed in a substantial majority
of pancreatic ductal and centroacinar
cells, there is considerable heterogeneity
in gene expression along the ductal
epithelial tree, and the distinct possibility
remains that PanIN can effectively origi-
nate from a subpopulation of Sox9-nega-
tive ductal epithelial cells. In addition, the
study by Kopp et al. (2012) relied on
tamoxifen-induced recombination in only
12% of all Sox9-expressing cells. As
acknowledged by the authors, this frac-
tion, when further reduced by a less
than uniform response to Kras even
among competent cell types, means that
rare Sox9-expressing cells (i.e., centroa-
cinar cells) might not have been effec-
tively interrogated in large numbers;
perhaps these cells account for the rare
PanIN lesion observed in these mice.
In spite of these caveats, it remains
difficult to escape the authors’ primary
conclusion that the predominant ductal
lineage in adult mouse pancreas re-
mains largely refractory to Kras-mediated
transformation.
While it is tempting to extend these
findings to the human disease, appro-
priate caution is warranted. In particular,
the current experimental paradigm only
evaluates what can happen, i.e., the
competence of individual adult murine
cell types to generate PanIN in response
to oncogenic Kras, as opposed to what
actually does happen under conditions
of spontaneous or carcinogen-induced
human KRAS mutations. Certainly,
murine PanIN induced by Kras activation
in either embryonic pancreas or in adult
acinar cells seems to bear exquisite
resemblance to human PanIN, both histo-
logically and with respect to gene expres-
sion patterns. However, prior analysis of
KRAS sequences in acinar cells adjacent
to human PanIN failed to identify mutant
alleles (Shi et al., 2009), suggesting that
acinar cell KRAS mutations are either
extremely rare or rapidly induce meta-
plastic or neoplastic conversion to a
non-acinar morphology. On the other
hand, cells with features of acinar differ-
entiation can often be identified in human
PanIN, and a subset of acinar to ductal
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Previewsmetaplasia (ADM) do, indeed, harbor
KRAS mutations identical to those ob-
served in adjacent PanIN (Shi et al.,
2009). These findings might be consistent
with KRAS mutations arising in either
acinar cells themselves or in areas of
ADM, with subsequent rapid progression
to PanIN.
Assuming that these findings are
indeed relevant to the human disease,
what are the ramifications of the current
findings? Certainly, they suggest that
future chemoprevention strategies might
be best targeted at early events in acinar
rather than ductal cells; blocking acinar
cell activation of Sox9 now joins Notch
pathway inhibition and maintenance of
Mist1 expression as examples of such
approaches. In addition, these findings
underscore an increasingly recognized
disconnect between Kras mutations and
Kras activity. Along these lines, it will be
fascinating to determine the presumably
epigenetic determinants underlying the
differential responsiveness to oncogenicKras observed in acinar and ductal cell
types; manipulating such determinants
may convert acinar cells into less capable
parents, hopefully eliminating PanIN from
the pancreatic family tree.REFERENCES
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Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these
agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance
to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.More than 25 years have passed since the
discovery of phosphoinositide 3-kinase
(PI3K) as an oncoprotein-associated
enzymatic activity. The term ‘‘PI3K’’ in
this context designates the Class I subset
of phosphoinositide kinases (comprising
the a, b, g, and d isoforms), which convert
phosphatidylinositol-4,5-bisphosphate to
the bioactive second messenger phos-
phatidylinositol-3,4,5-trisphosphate (Van-
haesebroeck et al., 2012). These PI3Ksare activated, directly or indirectly, by
a variety of cell surface receptors that
include receptor tyrosine kinases (RTKs)
and G protein-coupled receptors. Several
cardinal alterations elicited by PI3K acti-
vation include changes in cell prolifera-
tion, survival, migration, and metabolism,
and are highly aligned with the ‘‘hallmarks
of cancer’’ discussed by Hanahan and
Weinberg (2011). Indeed, inappropriate
activation of the PI3K pathway has beenobserved in a remarkably broad array of
human cancers. Nested within this pro-
oncogenic signaling network are two
pivotal protein serine-threonine kinases,
AKT (also termed protein kinase B) and
mTOR, both of which represent druggable
targets, like PI3K itself. This combination
of biological relevance and pharmaco-
logical tractability rendered the PI3K
pathway an irresistible target for cancer
drug discovery. The ensuing efforts inecember 11, 2012 ª2012 Elsevier Inc. 703
